(Q34207916)

31 July 2017

1 reference

title

Tumorigenesis in neurofibromatosis: new insights and potential therapies (English)

1 reference

31 July 2017

Reed N

1

1 reference

PubMed ID

11286939

31 July 2017

Gutmann DH

series ordinal

2

1 reference

31 July 2017

1 April 2001

1 reference

Trends in Molecular Medicine

31 July 2017

1 reference

31 July 2017

7

1 reference

31 July 2017

157-162

1 reference

31 July 2017

4

1 reference

cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

The neurofibromatosis type 1 gene encodes a protein related to GAP

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Regulators and Effectors of ras Proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Developmental regulation of a neuron-specific neurofibromatosis 1 isoform.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: a pathological and molecular explanation. Case report

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Tumour predisposition in mice heterozygous for a targeted mutation in Nf1

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Mouse models of tumor development in neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Mouse tumor model for neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Interdomain binding mediates tumor growth suppression by the NF2 gene product

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Merlin differentially associates with the microtubule and actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

The neurofibromatosis type 2 gene is inactivated in schwannomas

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901955-4

7 January 2021

10.1016/S1471-4914(01)01955-4

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11286939